Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
12 results
  • Liver Cancer, Gastric (Stomach) Cancer, Cervical Cancer

20-577          Phase I

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors (View details on

  • Metastatic/Advanced Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer

19-427          Phase I

A Phase 1 dose escalation study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors. (View details on

  • Gallbladder and Bile Duct Cancers, Liver Cancer, Brain Tumors, Sarcoma, Metastatic/Advanced Cancer

20-487          Phase I

A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (View details on

  • Brain Tumors, Metastatic, Liver Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Metastatic/Advanced Cancer, Lung Cancer

19-812          Phase I

A Phase 1, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in Patients with Advanced Solid Tumors Harboring Genetic Alterations in MET (View details on

  • Pancreatic Cancer, Esophageal Cancer, Sarcoma, Endometrial Cancer, Bladder Cancer, Gastric (Stomach) Cancer, Liver Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on

  • Liver Cancer, Cellular Therapy

17-033          Phase I

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) (View details on

  • Lung Cancer, Liver Cancer

20-451          Phase I

A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy (View details on

  • Liver Cancer

19-867          Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) (View details on

  • Liver Cancer

20-570          Phase I

A pilot study of neoadjuvant stereotactic beam radiation therapy followed by atezolizumab and bevacizumab in resectable hepatocellular carcinoma (View details on

  • Gallbladder and Bile Duct Cancers, Liver Cancer

20-645          Phase III

An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (View details on

Showing 1 - 10 of 12 results